Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/29/2871068/0/en/Atea-Announces-Presentation-of-Data-Highlighting-Favorable-Safety-Profile-of-Bemnifosbuvir-at-ESCMID-Global-2024.html
https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html
https://www.globenewswire.com//news-release/2024/02/28/2837414/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/21/2832614/0/en/Atea-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Conference-Call-on-February-28-2024.html
https://www.globenewswire.com//news-release/2024/01/08/2805848/0/en/Atea-Pharmaceuticals-Announces-Positive-Initial-Data-from-Phase-2-Study-for-Hepatitis-C-Virus-HCV-and-Significant-Enrollment-Milestone-for-Phase-3-SUNRISE-3-Trial-for-COVID-19.html
https://www.globenewswire.com//news-release/2024/01/03/2803148/0/en/Atea-Pharmaceuticals-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/13/2778876/0/en/Atea-Pharmaceuticals-Presents-Promising-Bemnifosbuvir-and-Ruzasvir-Combination-Data-for-the-Treatment-of-Hepatitis-C-Virus-at-AASLD-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/11/08/2776678/0/en/Atea-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2023/11/08/2776035/0/en/Atea-Pharmaceuticals-Announces-Participation-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2023/11/02/2772115/0/en/Atea-Pharmaceuticals-to-Present-Bemnifosbuvir-and-Ruzasvir-Data-for-the-Treatment-of-Hepatitis-C-Virus-at-AASLD-The-Liver-Meeting-2023.html